Table 2. Twenty-year cumulative results on health and validation outcomes, according to type of mammogram.

		Digital mammography		Screen-film mammography
		N	%	N	%
Overall data
Invited women		251,960		251,960
Initial population		100,000		100,000
New women entering target population		151,960		151,960
Screening mammograms		731,510		731,506
Initial screening		111,718	15.3%	111,718	15.3%
Successive screening		619,792	84.7%	619,788	84.7%
Recall for further assessment
Recall rate		44,536	6.1%	47,931	6.6%
Further assessments
Additional mammograms		19,085	2.6%	28,529	3.9%
Ultrasound		34,241	4.7%	37,809	5.2%
Fine-needle aspiration cytology		11,812	1.6%	20,729	2.8%
Core biopsy		2,725	0.4%	4,611	0.6%
Open surgical biopsy		302	0.04%	1,544	0.2%
False positive rate		39,833	5.4%	43,226	5.9%
Initial screening		12,812	11.5%	13,275	11.9%
Successive screening		27,021	4.4%	29,951	4.8%
Cancer detection
Cancer detection rate		4,702	0.643%	4,704	0.643%
Carcinoma in situ		1,008	21.4%	841	17.9%
Invasive cancers		3,694	78.6%	3,864	82.1%
Stage I		1,944	41.3%	2,073	44.1%
Stage II		1,380	29.4%	1,230	26.1%
Stage III		350	7.4%	549	11.7%
Stage IV		20	0.4%	13	0.3%
Interval cancer rate		1,588	0.217%	1,587	0.217%
True interval cancers (% of all cancers)		1,271	27.0%	1,271	27.0%
False negatives (% of all cancers)		316	6.7%	316	6.7%
Mortality
Deaths due to cancer		1,887	0.749%	1,942	0.771%
Carcinoma in situ		16	0.9%	14	0.7%
Stage I		444	23.6%	463	23.9%
Stage II		790	41.9%	791	40.7%
Stage III		424	22.5%	519	26.7%
Stage IV		159	8.5%	155	8.0%